Floundering, Lynx Closes $3M in Private Stock Placement | GenomeWeb

NEW YORK, Sept. 25 (GenomeWeb News) - Lynx Therapeutics has completed a $3 million private financing round of common stock and warrants for common stock, the struggling company said today.

The financing, made to certain undisclosed institutional investors, comprised the sale of 744,000 newly issued common shares at approximately $4.03 per share, and the issuance of warrants to buy 186,000 shares of common stock for around $9.91 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.